A Study of LY3209590 in Participants With Type 2 Diabetes Mellitus
Completed · Phase 2 · NCT03736785
Conditions: Type 2 Diabetes Mellitus
At a glance
- Research payments reported, 2025
- $4,287
- U.S. investigators named
- 5
- Sites paid
- 5
- Planned or actual enrollment
- 399
About the trial
- Sponsor
- Eli Lilly and Company
- Tested
- LY3209590 (drug), Insulin Degludec (drug)
- Dates
- Started 2018-11-15; completion 2020-02-18
- Results posted
- Yes
The reason for this study is to see if the study drug LY3209590 is safe and effective in participants with type 2 diabetes that have already been treated with basal insulin.
From ClinicalTrials.gov, last updated 2021-03-08. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Eli Lilly and Company reported $4,287 in research payments for this study in 2025 (5 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Anna R. Chang, M.D. Internal Medicine · Concord, CA
- Alan G. Wynne, MD Endocrinology & Diabetes · Topeka, KS
- Betsy M. Palal, M.D Endocrinology & Diabetes · Las Vegas, NV
- Robert J. Silver, M.D. Endocrinology & Diabetes · Brooklyn, NY
- Douglas S. Denham, D.O. Family Medicine · San Antonio, TX
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- John Muir Med Fndtn DBA John Muir Phys Network $1,290
- Clinical Trials of Texas Inc $1,230
- Foundation Medical PArtners Inc $1,119
- Palm Research Center Inc $392
- Imic Inc $257
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.